This guideline updates the previous guidelines,听 published on behalf of the 91黄网 (BSH) and the United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO), focusing on the laboratory components of diagnosis and monitoring. Clinical aspects will be addressed in a separate guideline.
This guideline describes laboratory tests used to diagnose and monitor individuals with von Willebrand disease (VWD). Since the publication of the previous guideline,听new functional tests have become widely available as an alternative to the ristocetin cofactor assay. This guideline also updates genetic testing rationale and highlights the American College of Medical Genetics and Genomics (ACMG) guidelines for interpretation of sequence variants,听听and Association for Clinical Genomic Science (ACGS) guidelines for variant interpretation.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.